New Three-Year Real-World LEQEMBI® Data Presented at CTAD 2026

Largest analysis of LEQEMBI LEADER study reported to date includes findings on amyloid clearance in routine clinical practice, delayed progression to moderate or severe AD, expanded subcutaneous maintenance experience, and additional sex-based outcomes TOKYO and CAMBRIDGE, Mass., Nov. 18,…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks